Company Analysis
Sign in

LENZ Therapeutics, Inc. (LENZ)

Nasdaq: LENZ · Biological Products, (No Diagnostic Substances) · Solana Beach, CA · filing with the SEC since 2021
Full chart Alerts Compare
Grade5.6
◀ Past 6.5● Present 5.8▶ Future 4.8
5 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

9 patents granted to the 5 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to LENZ Therapeutics, Inc.’s names, not what it holds today.

Patents granted
9
9 utility, 1976 to Dec 31, 2025
Granted in 2025
1
Against 2 in 2024 and 1 in 2023
Applications published
21
3 of them in 2025
Names they are printed under
5
its own name, a former name, a subsidiary
By yearGrantedApplications published
'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals8
Organic fine chemistry1
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name5 counted
Lenz Therapeutics, Inc. its own name
named as the applicant on its applications, in US
0 granted
15 published
Lenz Therapeutics, Inc. its own name
US, as the owner printed on each patent
6 granted
0 published
Graphite Bio, Inc. a former name
named as the applicant on its applications, in US
0 granted
4 published
LENZ THERAPEUTICS OPERATIONS, INC. a subsidiary
US, as the owner printed on each patent
3 granted
0 published
Lenz Therapeutics Operations, Inc. a subsidiary
named as the applicant on its applications, in US
0 granted
2 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Sep 16, 202512,414,942Compositions, methods, and systems for treating presbyopiaPharmaceuticalsLENZ THERAPEUTICS OPERATIONS, INC.
Dec 31, 202412,180,206Aceclidine derivatives, compositions thereof and methods of use thereofPharmaceuticalsLENZ THERAPEUTICS OPERATIONS, INC.
Oct 29, 202412,128,036Compositions and methods for storage stable ophthalmic drugsPharmaceuticalsLENZ THERAPEUTICS OPERATIONS, INC.
May 16, 202311,648,247Compositions and methods for the treatment of presbyopiaPharmaceuticalsLenz Therapeutics, Inc.
May 31, 202211,344,538Methods for the treatment of myopiaPharmaceuticalsLenz Therapeutics, Inc.
Mar 15, 202211,273,150Compositions and methods for the treatment of presbyopiaPharmaceuticalsLenz Therapeutics, Inc.
Jan 4, 202211,214,569Prodrugs of quinuclidine ring-containing muscarinic agonists and compositions and methods thereofOrganic fine chemistryLenz Therapeutics, Inc.
Nov 23, 202111,179,328Compositions and methods for the treatment of presbyopiaPharmaceuticalsLenz Therapeutics, Inc.
Nov 23, 202111,179,327Compositions and methods for the treatment of presbyopiaPharmaceuticalsLenz Therapeutics, Inc.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Dec 25, 20252025/0389953METHODS AND SYSTEMS FOR A SIMULATED FIELD OF VIEW AFFECTED BY AN OPHTHALMIC CONDITIONOpticsLenz Therapeutics Operations, Inc.
Sep 18, 20252025/0288566COMPOSITIONS, METHODS, AND SYSTEMS IN TREATING PRESBYOPIAPharmaceuticalsLenz Therapeutics Operations, Inc. · patent 12,414,942 granted from it
Jun 19, 20252025/0197458ADAPTATIONS FOR HIGH EFFICIENCY I-F3-CRISPR-CAS SYSTEMS FOR GUIDE RNA-DIRECTED TRANSPOSITION IN HUMAN CELLSBiotechnologyGraphite Bio, Inc.
May 16, 20242024/0156873METHODS TO GENETICALLY ENGINEER HEMATOPOIETIC STEM AND PROGENITOR CELLS FOR RED CELL SPECIFIC EXPRESSION OF THERAPEUTIC PROTEINSBiotechnologyGraphite Bio, Inc.
Apr 18, 20242024/0122989METHODS AND COMPOSITIONS FOR PRODUCTION OF GENETICALLY MODIFIED PRIMARY CELLSBiotechnologyGraphite Bio, Inc.
Mar 21, 20242024/0091207COMPOSITIONS AND METHODS FOR STORAGE STABLE OPHTHALMIC DRUGSPharmaceuticalsLenz Therapeutics, Inc.
Dec 28, 20232023/0414587COMPOSITIONS AND METHODS FOR STORAGE STABLE OPHTHALMIC DRUGSPharmaceuticalsLenz Therapeutics, Inc. · patent 12,128,036 granted from it
Dec 28, 20232023/0414494COMPOSITIONS AND METHODS FOR THE TREATMENT OF PRESBYOPIAPharmaceuticalsLenz Therapeutics, Inc.
Dec 21, 20232023/0404912COMPOSITIONS AND METHODS FOR THE TREATMENT OF PRESBYOPIAPharmaceuticalsLenz Therapeutics, Inc.
Dec 14, 20232023/0398113COMPOSITIONS AND METHODS FOR THE TREATMENT OF PRESBYOPIAPharmaceuticalsLenz Therapeutics, Inc.
What it applied for, 2024 to 2025: Biotechnology 3 · Pharmaceuticals 2 · Optics 1.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton LENZ · research, not advice